IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Recommendation of “Buy” by Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given an average rating of “Buy” by the seventeen ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $229.1250.

A number of equities analysts have recently issued reports on IQV shares. Evercore reiterated an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a report on Thursday, February 5th. Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a report on Friday, February 6th. Mizuho set a $215.00 target price on shares of IQVIA in a report on Monday, February 23rd. Finally, Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research note on Friday, March 6th.

Hedge Funds Weigh In On IQVIA

A number of large investors have recently bought and sold shares of the stock. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA during the 4th quarter valued at $27,000. CrossGen Wealth LLC bought a new stake in IQVIA in the 4th quarter worth $28,000. Finally, Activest Wealth Management increased its position in shares of IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $170.50 on Friday. The company’s fifty day moving average price is $184.00 and its 200-day moving average price is $205.18. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market capitalization of $28.93 billion, a price-to-earnings ratio of 21.69, a PEG ratio of 1.60 and a beta of 1.39. IQVIA has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.